Human Antibodies & Hybridomas

7-9 November 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 7th November

09.10-09.15
Welcome & Opening Remarks
Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

SESSION 1:
OPENING PLENARY

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

09.15-09.45
‘Novel applications of antibody therapeutics in cardiovascular medicine’
James W. Larrick (Panorama Research Institute, Sunnyvale, California, USA)

09.45-10.15
‘Generation of human antibodies using somatic hypermutation in vitro
David King (AnaptysBio Inc., San Diego, California, USA)

10.15-10.45
‘A modular antibody technology to create bispecific mAb2’
John Haurum (f-Star, Cambridge, UK)

10.45-11.05
Coffee Break

SESSION 2:
CANCER I

Moderator: David Naor (The Hebrew University, Jerusalem, Israel)

11.05-11.30
‘The potential of natural B cells in a tumor microenvironment’
Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

11.30-11.55
‘Long-lasting anti-tumor protection through adaptive immune response induced by anti-CD20 mAb treatment’
Jean-Luc Teillaud (INSERM / Cordeliers Research Center, Paris, France)

11.55-12.20
‘Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells’
Serge Krysov, Samantha Dias, Alex Paterson, C. Ian Mockridge, Kathleen N. Potter, Kelly-Ann Smith, Margaret Ashton-Key, Freda Stevenson and Graham Packham (University of Southampton, Southampton, UK)

12.20-12.45
‘Antibody-drug conjugates (ADCs): The next wave of antibody-based anti-cancer agents?’
John Lambert (Immunogen Inc., Waltham, Massachusetts, USA)

12.45-14.00
Lunch Break

SESSION 3:
AUTOIMMUNITY

Moderator: James W. Larrick (Panorama Research Institute, Sunnyvale, California, USA)

14.00-14.30
‘Hyaluronic acid target receptors (CD44 and RHAMM) involved in treatment of type 1 diabetes’
David Naor (The Hebrew University, Jerusalem, Israel)

14.30-14.50
‘Preliminary safety and pharmacokinetics of GNbAC1, a humanized monoclonal antibody antagonist of the multiple sclerosis retrovirus envelope protein’
Alois B. Lang (GeNeuro SA, Geneva, Switzerland)

14.50-15.10
‘Therapeutic antibodies to treat inflammatory diseases’
Steven Coats (MedImmune Inc., Gaithesburg, Maryland, USA)

15.10-15.30
‘Citrullinated epitope as target for novel therapeutic antibodies in RA’
Jos Raats (ModiQuest Research, Nijmegen, The Netherlands)

15.30-16.00
Tea Break

SESSION 4:
INFECTIOUS DISEASES I

Moderator: Alois B. Lang (GeNeuro SA, Geneva, Switzerland)

16.00-16.30
‘Discovery & development of human B-cell derived therapeutic monoclonal antibody candidates for indications of infectious disease’
Kristine Swiderek (Theraclone Sciences, Seattle, Washington, USA)

16.30-17.00
‘Discovery of unique human monoclonal antibodies that counteract staphylococcal virulence factors’
Ester Nagy (Arsanis GmbH, Vienna, Austria)

17.00-17.20
‘Cross-neutralizing activity of human anti-HIV-1 monoclonal antibodies do not correlate with the percentage of mutations in their variable fragments’
Miroslaw K. Gorny, Constance Williams, Barbara Volsky, Xiao-Hong Wang, Liuzhe Li, Michael S. Seaman and Susan Zolla-Pazner (New York University, New York, USA)

17.20-17.40
‘Immune complex vaccines to elicit antibodies against HIV-1 neutralizing epitopes’
Catarina E. Hioe, Rajnish Kumar, Maria Luisa Visciano, Hualin Li and Michael Tuen (New York University School of Medicine, New York, USA)

17.40-18.00
‘MB-2003: an antibody based immunoprotectant for Ebola virus’
Larry Zeitlin (MAPP Biopharmaceuticals Inc., San Diego, California, USA)

18.00-19.00
HAH 2012 Welcome Drinks Reception

 

HAH 2012 Delegates

Login details will be supplied after you have registered for the event.


HAH 2012 Sponsors

  • Arsanis Biosciences
  • Fusion Antibodies
  • UCB Celltech
  • Intercell
  • Regeneron
  • ImClone Systems
  • Novartis Vaccines
  • Fenwick & West
  • CytomX Therapeutics
  • Theraclone Sciences
  • Becton Dickinson
  • Symphogen
  • Aldevron
  • Genentech
  • Affimed
  • ModiQuest
  • Kadmon
  • Mapp Biopharmaceutical
  • GlaxoSmithKline
  • Kenta Biotech
  • Nascent Biologics
  • Morphotek
  • Adimab
  • ImmunoGen
  • Geneuro
  • OMT
  • Morphosys
  • Selexis
  • Dyax
  • Catalent
  • Immunome
  • Retroscreen Virology

HAH 2012 Downloads

HAH 2012 Leaflet

HAH 2012 Mailing List

Name
E-mail Address
What is 1+4-2?